Table 1.
Associations between question items and social disadvantages (Spearman rank correlation)
| Correlation (95% CI) with social disadvantages, p Value |
|||
|---|---|---|---|
| Question item | Unemployment or unwilling transfer (213/486 cases) | Decrease in income (244/486 cases) | Reduced social positivity (449/486 cases) |
| 1. Insufficient control of symptoms | 0.19 (0.095 to 0.285), <0.0001 | 0.08 (−0.01 to 0.18), 0.05 | 0.05 (−0.04 to 0.14), 0.13 |
| 2. Depressive state, changes in mood or character after PSL (PSL use, 81% of subjects) | 0.10 (0.00 to 0.19), 0.03 | 0.02 (−0.08 to 0.12), 0.36 | 0.20 (0.10 to 0.28), <0.0001 |
| 3. Changes in appearance after PSL (PSL use, 81% of 486 participants) | 0.07 (−0.03 to 0.16), 0.10 | 0.05 (−0.05 to 0.15), 0.14 | 0.20 (0.11 to 0.28), <0.0001 |
| 4. Diabetes mellitus, osteoporosis, cataracta and/or other arteriosclerotic diseases (PSL use, 81% of participants) | 0.05 (−0.05 to 0.15), 0.16 | 0.13 (0.03 to 0.22), 0.006 | 0.12 (0.03 to 0.21), 0.005 |
| 5. Side effects related to non-steroid immunosuppressive agents (CNI use, 53%; AZA use, 5%) | −0.02 (−0.12 to 0.07), 0.31 | 0.05 (−0.05 to 0.15), 0.16 | 0.08 (−0.01 to 0.17), 0.04 |
| 6. Adverse events related to plasmapheresis (28%) | 0.04 (−0.06 to 0.14), 0.21 | 0.07 (−0.03 to 0.17), 0.08 | 0.04 (−0.05 to 0.13), 0.20 |
| 7. Adverse events related to intravenous immunoglobulin (16%) | 0.05 (−0.05 to 0.15), 0.17 | 0.07 (−0.03 to 0.17), 0.08 | 0.06 (−0.03 to 0.15), 0.08 |
| 8. Long-term (>1 month) hospital stay | 0.20 (0.10 to 0.29), <0.0001 | 0.27 (0.19 to 0.37), <0.0001 | −0.05 (−0.14 to 0.04), 0.12 |
| 9. Short-term (≤1 week) hospital stay | 0.12 (0.02 to 0.24), 0.006 | 0.13 (0.04 to 0.23), 0.003 | 0.09 (0.00 to 0.17), 0.03 |
| 10. Need to go to the hospital for years | 0.16 (0.07 to 0.26), <0.001 | 0.15 (0.06 to 0.25), <0.001 | 0.03 (−0.06 to 0.12), 0.25 |
| 11. Need to take various oral drugs for years | 0.05 (−0.05 to 0.15), 0.16 | 0.07 (−0.03 to 0.16), 0.10 | 0.13 (0.04 to 0.21), 0.002 |
| 12. Bias for intractable and uncommon diseases from others | 0.16 (0.06 to 0.26), <0.001 | 0.02 (−0.08 to 0.12), 0.35 | 0.21 (0.12 to 0.30), <0.0001 |
Significant correlations are indicated by bold font.
AZA, azathioprine; CNI, calcineurin inhibitor; PSL, prednisolone.